Hylek EM - Search Results

1

Female sex as an independent risk factor for stroke in atrial fibrillation: possible mechanisms.

Cove CL, Albert CM, Andreotti F, Badimon L, Van Gelder IC, Hylek EM. Cove CL, et al. Among authors: hylek em. Thromb Haemost. 2014 Mar 3;111(3):385-91. doi: 10.1160/TH13-04-0347. Epub 2013 Dec 5. Thromb Haemost. 2014. PMID: 24305974 Review.

2

Factor V Leiden and risk of ischemic stroke in nonvalvular atrial fibrillation: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study.

Go AS, Reed GL, Hylek EM, Phillips KA, Liu L, Henault LE, Selby JV, Singer DE. Go AS, et al. Among authors: hylek em. J Thromb Thrombolysis. 2003 Feb;15(1):41-6. doi: 10.1023/a:1026192301848. J Thromb Thrombolysis. 2003. PMID: 14574075

3

Contra: 'Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation'. Caveats regarding use of oral anticoagulant therapy among elderly patients with atrial fibrillation.

Hylek EM. Hylek EM. Thromb Haemost. 2008 Jul;100(1):16-7. doi: 10.1160/TH08-06-0343. Thromb Haemost. 2008. PMID: 18612532 No abstract available.

4

Disparate stroke rates on warfarin among contemporaneous cohorts with atrial fibrillation: potential insights into risk from a comparative analysis of SPORTIF III versus SPORTIF V.

Hylek EM, Frison L, Henault LE, Cupples A. Hylek EM, et al. Stroke. 2008 Nov;39(11):3009-14. doi: 10.1161/STROKEAHA.108.514935. Epub 2008 Aug 14. Stroke. 2008. PMID: 18703812

5

Oral anticoagulant therapy for patients with atrial fibrillation--an update.

Hylek EM. Hylek EM. Thromb Res. 2008;123 Suppl 1:S46-9. doi: 10.1016/j.thromres.2008.08.016. Epub 2008 Sep 21. Thromb Res. 2008. PMID: 18809205 Review. No abstract available.

6

Warfarin for atrial fibrillation in community-based practise.

Rose AJ, Ozonoff A, Henault LE, Hylek EM. Rose AJ, et al. Among authors: hylek em. J Thromb Haemost. 2008 Oct;6(10):1647-54. doi: 10.1111/j.1538-7836.2008.03075.x. J Thromb Haemost. 2008. PMID: 18853483 Free article.

7

Antithrombotic prophylaxis in elderly patients with atrial fibrillation.

Hylek EM. Hylek EM. Semin Thromb Hemost. 2009 Sep;35(6):548-53. doi: 10.1055/s-0029-1240015. Epub 2009 Sep 28. Semin Thromb Hemost. 2009. PMID: 19787558

8

Anticoagulation for valvular heart disease in community-based practice.

Rose AJ, Ozonoff A, Henault LE, Hylek EM. Rose AJ, et al. Among authors: hylek em. Thromb Haemost. 2010 Feb;103(2):329-37. doi: 10.1160/TH09-07-0450. Epub 2009 Dec 18. Thromb Haemost. 2010. PMID: 20024499

9

New-onset atrial fibrillation and warfarin initiation: high risk periods and implications for new antithrombotic drugs.

Garcia DA, Lopes RD, Hylek EM. Garcia DA, et al. Among authors: hylek em. Thromb Haemost. 2010 Dec;104(6):1099-105. doi: 10.1160/TH10-07-0491. Epub 2010 Sep 30. Thromb Haemost. 2010. PMID: 20886196 Review.

10

Future directions of stroke prevention in atrial fibrillation: the potential impact of novel anticoagulants and stroke risk stratification.

Cabral KP, Ansell J, Hylek EM. Cabral KP, et al. Among authors: hylek em. J Thromb Haemost. 2011 Mar;9(3):441-9. doi: 10.1111/j.1538-7836.2010.04179.x. J Thromb Haemost. 2011. PMID: 21176102 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

279 results

Search Page

Filters